Immunic (IMUX) Competitors $0.79 -0.06 (-6.77%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.80 +0.00 (+0.21%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. CGC, TECX, AMRN, KRRO, DRUG, OCGN, GLUE, SCPH, CAPR, and GALTShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Canopy Growth (CGC), Tectonic Therapeutic (TECX), Amarin (AMRN), Korro Bio (KRRO), Bright Minds Biosciences (DRUG), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), scPharmaceuticals (SCPH), Capricor Therapeutics (CAPR), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Its Competitors Canopy Growth Tectonic Therapeutic Amarin Korro Bio Bright Minds Biosciences Ocugen Monte Rosa Therapeutics scPharmaceuticals Capricor Therapeutics Galectin Therapeutics Canopy Growth (NASDAQ:CGC) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Is CGC or IMUX more profitable? Immunic has a net margin of 0.00% compared to Canopy Growth's net margin of -155.76%. Canopy Growth's return on equity of -89.93% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Canopy Growth-155.76% -89.93% -44.24% Immunic N/A -461.46%-217.16% Do institutionals & insiders have more ownership in CGC or IMUX? 3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Comparatively, 4.6% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer CGC or IMUX? In the previous week, Canopy Growth had 2 more articles in the media than Immunic. MarketBeat recorded 7 mentions for Canopy Growth and 5 mentions for Immunic. Canopy Growth's average media sentiment score of 1.53 beat Immunic's score of 0.74 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunic 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, CGC or IMUX? Canopy Growth has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Which has preferable valuation and earnings, CGC or IMUX? Immunic has lower revenue, but higher earnings than Canopy Growth. Immunic is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCanopy Growth$225.65M1.46-$429.86M-$3.03-0.45ImmunicN/AN/A-$100.51M-$0.94-0.85 Do analysts rate CGC or IMUX? Immunic has a consensus target price of $8.33, indicating a potential upside of 949.14%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33Immunic 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryImmunic beats Canopy Growth on 10 of the 16 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.05M$3.20B$5.86B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-0.8521.1774.5225.93Price / SalesN/A472.61547.62126.81Price / CashN/A46.6837.5660.44Price / Book3.979.6112.166.29Net Income-$100.51M-$53.29M$3.28B$270.77M7 Day Performance4.38%0.28%0.87%3.88%1 Month Performance-4.22%5.73%4.96%4.88%1 Year Performance-47.74%10.52%60.75%26.01% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.4432 of 5 stars$0.79-6.8%$8.33+949.1%-46.7%$84.05MN/A-0.8570Gap UpCGCCanopy Growth0.9473 of 5 stars$1.36-7.2%N/A-71.0%$325.00M$225.65M-0.453,150Positive NewsShort Interest ↓Gap UpTECXTectonic Therapeutic3.207 of 5 stars$16.44-2.1%$80.29+388.3%+1.3%$308.56MN/A-4.08120Positive NewsAMRNAmarin0.608 of 5 stars$14.86-3.1%$12.00-19.2%+29.0%$308.22M$228.61M-4.06360KRROKorro Bio2.2306 of 5 stars$32.80-1.2%$86.83+164.8%-23.9%$303.63M$2.27M-3.3270Positive NewsHigh Trading VolumeDRUGBright Minds Biosciences3.4035 of 5 stars$42.68+1.0%$81.00+89.8%+3,800.0%$301.38MN/A-46.03N/APositive NewsOCGNOcugen1.7672 of 5 stars$1.03-0.5%$6.00+485.4%-10.8%$299.61M$4.05M-5.1280GLUEMonte Rosa Therapeutics2.676 of 5 stars$4.81-2.7%$15.33+219.1%-19.3%$298.55M$75.62M13.4390Positive NewsSCPHscPharmaceuticals4.5104 of 5 stars$5.58+0.1%$7.78+39.6%+6.0%$297.15M$36.33M-3.0830Short Interest ↓CAPRCapricor Therapeutics2.1947 of 5 stars$6.42-4.8%$22.56+251.6%+52.2%$293.57M$22.27M-3.92101Analyst ForecastGALTGalectin Therapeutics1.3317 of 5 stars$4.61+0.2%$6.00+30.2%+98.2%$292.43MN/A-7.139Positive NewsGap Up Related Companies and Tools Related Companies Canopy Growth Alternatives Tectonic Therapeutic Alternatives Amarin Alternatives Korro Bio Alternatives Bright Minds Biosciences Alternatives Ocugen Alternatives Monte Rosa Therapeutics Alternatives scPharmaceuticals Alternatives Capricor Therapeutics Alternatives Galectin Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMUX Stock Alerts